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Duck HBV (DHBV)We explored in the duck hepatitis B virus (DHBV) model the impact of electroporation (EP)-mediated DNA
vaccine delivery on the neutralizing humoral response to viral preS/S large envelope protein. EP enhanced
the kinetics and magnitude of anti-preS response compared to the standard needle DNA injection (SI). Im-
portantly, EP dramatically enhanced the neutralizing potency of the humoral response, since antibodies in-
duced by low DNA dose (10 μg) were able to highly neutralize DHBV and to recognize ten antigenic
regions, including four neutralization epitopes. Whereas, SI-induced antibodies by the same low DNA dose
were not neutralizing and the epitope pattern was extremely narrow, since it was limited to only one epi-
tope. Thus, EP-based delivery was able to improve the dose efﬁciency of DNA vaccine and to maintain a highly
neutralizing, multi-speciﬁc B-cell response, suggesting that it may be an effective approach for chronic hep-
atitis B therapy at clinically feasible DNA dose.
© 2012 Elsevier Inc. All rights reserved.Introduction
Viral persistence in patients chronically infected with hepatitis B
virus (HBV) is typically associated with weakness or impairment of
speciﬁc immune responses, whereas clearance of infection is known
to be dependent of appropriate immune responses to viral antigens
(Rehermann and Nascimbeni, 2005). The humoral immune response,
by generating protective antibodies, contributes to the neutralization
of circulating viral particles and the prevention of viral spread within
the host. In addition, HBV-speciﬁc T-cell responses clear viral infec-
tion from hepatocytes, initially through type 1 inﬂammatory cytokine
(IFN-γ, TNF-α) secretion which noncytopathically abolishes HBV
gene expression and then, through the production of cytotoxic mole-
cules leading to the apoptosis of hepatocytes (Chisari et al., 2010). In
this regard, DNA vaccination able to stimulate both humoral and cel-
lular arms of the immune response, has been proposed as a potential-
ly promising strategy for chronic hepatitis B therapy (Michel et al.,
2011). A DNA-based vaccine targeting HBV envelope proteins was
shown to induce potent immune responses particularly with a Th1
cytokine proﬁle, leading to the suppression of viral replication inrs Albert Thomas, 69424, Lyon
rights reserved.transgenic mice (lineage E36) (Mancini et al., 1996). However, trans-
lating the success of DNA vaccines frommice to larger species, such as
agriculturally important animals and humans, has not been very suc-
cessful. It appears that DNA uptake and expression as well as recruit-
ment of antigen-presenting cells to the injection site are less efﬁcient
in larger species compared to rodents (Luxembourg et al., 2007).
Electroporation (EP)-mediated delivery of DNA vaccines has been
demonstrated to clearly outperform the standard needle injection
(SI) of plasmid DNA (pDNA), via increasing cellular permeability,
which results in high level protein expression and improved immu-
nogenicity to DNA vaccines targeting different viruses in a number
of animal models including large animal species and non human pri-
mates (Ahlen et al., 2007; Capone et al., 2006; Livingston et al., 2010;
Luckay et al., 2007; Otten et al., 2004; Rosati et al., 2008; van Drunen
Littel-van den Hurk et al., 2008, 2010). For HBV, it has been reported
that EP-based delivery dramatically enhances humoral and cellular
immune responses to DNA vaccines targeting HBV envelope and/or
core antigens, in several animal species such as mice (Chen et al.,
2011; Kim et al., 2008; Luxembourg et al., 2006, 2008b; Peng et al.,
2007; Widera et al., 2000), rabbit (Luxembourg et al., 2006, 2008b),
sheep (Babiuk et al., 2007), pigs (Babiuk et al., 2002, 2004), cattle
(van Drunen Littel-van den Hurk et al., 2008), rhesus-macaques
(Zhao et al., 2006) and recently in the woodchuck model (Liu et al.,
2011). In these studies, cellular immune responses to HBV antigens
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the antigen-speciﬁc T cell frequency by several-fold and to induce
multiple T-cell effector functions, including IFN-γ production and cy-
totoxic T lymphocyte (CTL) activity as compared to standard needle
injection (SI). EP-based DNA delivery was also shown to induce a
broader repertoire of cellular responses against immunodominant
and subdominant T-cell epitopes for a given vaccine (Kim et al.,
2008; Luxembourg et al., 2006). Concerning the humoral response,
it has been shown to be enhanced by several-fold using EP-based de-
livery system. However, neutralizing potency of generated antibodies
to HBV DNA vaccines was not yet investigated due to the lack of ro-
bust cell system allowing in vitro analysis of HBV infectivity.
In this regard, the closely related duck HBV (DHBV) provides a
very useful model to investigate the breadth of humoral response in-
duced by EP-based delivery of DNA vaccine targeting hepadnavirus
envelope proteins since generated antibodies can be studied in vitro
in primary duck hepatocyte (PDH) cultures for their ability to neutral-
ize DHBV infectivity (Cova and Zoulim, 2004; Rollier et al., 1999). Two
major carboxy-terminal proteins have been identiﬁed within the
DHBV envelope: a large (preS/S: L, 36 kDa) and a small (S, 18 kDa)
surface protein, both required for DHBV infectivity. We and others
have previously mapped the major DHBV neutralizing epitopes with-
in the N-terminal preS domain of the DHBV L protein using monoclo-
nal antibodies (Chassot et al., 1993; Yuasa et al., 1991). We have also
characterized at the amino acid level the major B-cell epitopes on the
DHBV preS protein involved in the immune response of adult ducks to
DHBV (Chassot et al., 1994). Moreover, we have previously demon-
strated in this model that immunization of naïve ducks with standard
intramuscular (i.m.) injection (SI) of pDNA encoding the DHBV preS/S
L envelope protein induced a strong, speciﬁc and long-lasting humor-
al response that was able to neutralize DHBV in experimentally
infected hepatocytes and to protect neonatal ducklings from viral in-
fection (Rollier et al., 1999).
In the present study, we have investigated whether EP-based de-
livery could further increase the magnitude and breadth of humoral
response to the DNA vaccine expressing DHBV L protein. In addition
to the kinetics and the dose–response efﬁciency, we also examined
the speciﬁcity of generated antibodies, and more importantly, the
neutralizing efﬁcacy of the anti-preS antibody response. Moreover,
an important aspect of this study concerns the ﬁrst comparison, at(A)
(B)
(C)
Fig. 1. DNA immunization of ducks against DHBV L protein. (A) Study 1: Animals were rand
the DHBV large envelope protein either by EP or by SI. The control group received the same d
assigned randomly into six groups which received different amounts of pCI-preS/S plasmi
empty pCI plasmid. (C) Design of experimental protocol. DNA injections were performed a
week 30. The humoral response was followed during the entire immunization protocol andthe amino acid level, of B-cell epitope speciﬁcity of the humoral re-
sponse induced by pDNA administrated either by EP or SI. This
study in the DHBV model reveals the beneﬁts of EP-based pDNA de-
livery on the biological properties of generated antibodies.
Results
Enhanced preS antigen expression and acute inﬂammatory cell inﬁltra-
tion following in vivo DNA EP
To study the effect of EP-based DNA delivery in animals on preS
protein expression and the local inﬂammatory response at the site
of injection, immunohistological examination was carried out on tis-
sue from the injection sites sampled 6 days after administration of
pCI-preS/S plasmid either by SI or EP. As expected, following EP of
physiological saline solution (control group), an inﬂammatory re-
sponse and preS expression were not detected at the injection site
(Fig. 2 panels A, D, G). Similarly, the SI of 300 μg of pCI-preS/S did
not cause any detectable tissue damage (Fig. 2C). A local inﬂammato-
ry response was undetectable (Fig. 2F) and preS protein expression
was not detected at day 6 post immunization (Fig. 2I). By contrast,
the combination of pCI-preS/S injection with in vivo EP induced an
acute local inﬂammation as illustrated in Fig. 2B. Importantly, the in-
ﬂammatory inﬁltrate in the electroporated muscle contained a large
proportion of CD3+ T cells (Fig. 2E). In addition, DNA EP led to
more sustained preS protein expression in muscle ﬁbers as compared
with SI since at day 6 post-DNA EP, the expression of preS was still
detectable at the injection site (Fig. 2H). Thus, in vivo EP delivery of
the pCI-preS/S DNA vaccine increased and prolonged DHBV preS an-
tigen expression, enhanced local inﬂammation and inﬁltration of
CD3+ T cells, and resulted in limited local tissue damage (data not
shown).
Kinetics of anti-preS antibody response in duck following SI or EP DNA
delivery
To examine the potential of EP to enhance immune responses
against the DHBV L envelope protein, ducks were immunized with
300 μg of pCI-preS/S plasmid using in vivo EP or SI, at weeks 0, 4,
8 and 30, whereas a control group received an empty pCI plasmid.omly assigned into two groups, which received 300 μg of pCI-preS/S plasmid encoding
ose of empty pCI plasmid. (B) Study 2: To evaluate the effect of DNA dose, animals were
d (ranging from 10 to 150 μg) delivered either by EP or by SI. Control ducks received
t weeks 0, 4, and 8. Ducks from the 1st study received an additional delayed boost on
was continued for 4 weeks after the last immunization.
Fig. 2. Immunohistopathology of injection sites. Ducks were immunized intramuscularly with (A,D,G) phosphate buffered saline, (B,E,H) 300 μg pCI-preS/S plasmid by in vivo EP or
(C,F,I) by SI and sacriﬁced at day 6 post injection for immunohistological analysis. Muscle sections (5 μm) were stained with H&E (A,B,C) or with an antibody to CD3 (D,E,F) or preS
protein (G,H,I) on day 6 following immunization. The lower panel (J–L) represents control staining obtained with anti-rabbit conjugates in the absence of primary anti-preS anti-
body. Magniﬁcation ×10 (A, B, C, D, E, F) ×40 (G, H, I, J, K, L).
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able anti-preS response. In contrast, starting 4 weeks after the ﬁrst
DNA immunization with pCI-preS/S, a humoral response was
detected with a similar pattern in duck groups immunized either by
EP or SI. This response was further enhanced after the second DNA
administration with the EP group showing a more rapid rise in anti-
preS response, which reached signiﬁcantly higher titers at week 5
that were 16-fold greater (pb0.05) as compared with the SI group
(Fig. 3). In spite of apparently higher mean antibody titers observed
for the EP group, starting after the third DNA administration, there
was no signiﬁcant difference in antibody titers between the EP and
the SI group at weeks 16 and 24. By contrast, following the ﬁnal im-
munization, ducks immunized by pDNA EP showed signiﬁcantly
higher anti-preS titers (pb0.05) (titers peaking to 104.5) compared
with the SI group (titers peaking to 103.9). Taken together, these re-
sults suggest that in vivo EP is a potent delivery method that enhances
the magnitude and maintenance of antibody responses to a DNAvaccine. We next assessed whether these features were maintained
over a broad range of DNA doses. To investigate the dose–response
to DNA delivered with EP, ducks were immunized with 10, 50 and
150 μg of pCI-preS/S plasmid either by EP or SI at weeks 0, 4 and 8.
As shown in Fig. 4, when DNA was delivered by EP, the induced
anti-preS titers were higher as compared with those induced by SI
for the same DNA dose. This difference was statistically signiﬁcant
(pb0.05) after the second and the last boost (week 5 and 9 respec-
tively). Interestingly, the delivery of only 50 μg of DNA by EP led to
a higher magnitude of anti-preS response, with a signiﬁcant differ-
ence (pb0.03) after the second boost, as compared with anti-preS re-
sponse induced by a 3-fold higher (150 μg) DNA dose administrated
by needle conventional injection. More importantly, even the lowest
DNA dose (10 μg) delivered by EP resulted in the induction of high
anti-preS titers comparable to those elicited by a 15-fold higher
dose of DNA administrated by SI. Thus, EP-based delivery dramatical-
ly enhanced the dose efﬁciency of the DNA vaccine.
Fig. 3. Kinetics of humoral response elicited by DNA immunization against DHBV L pro-
tein. The graph shows the mean anti-preS responses for each duck group immunized
with pCI-preS/S delivered by in vivo EP or by SI or with empty pCI vector administrated
by EP (controls). Detection of anti-preS end point titers, expressed as log 10, was per-
formed using a direct ELISA test. Black arrows indicate DNA injections. Statistically sig-
niﬁcant differences of the EP group relative to the SI group are shown * (pb0.05) using
a two-tailed Mann–Whitney test assuming a Gaussian approximation.
Fig. 5. Recognition of DHBV L protein by immunoblotting. Pooled sera from ducks im-
munized with 300 μg of pCI-preS/S by EP or SI were brought back to the same anti-preS
titer for testing their speciﬁcity regarding the preS/S protein. DHBV proteins concen-
trated from LMHD2 supernatants were probed with pooled sera from A) DNA EP-
immunized group, B) DNA SI-immunized group and with C) mouse monoclonal anti-
preS antibody (Chassot et al., 1993) used as positive control.
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We tested pooled sera from each group, at the same anti-preS an-
tibody titer, for their ability to recognize the DHBV L envelope protein
(preS/S). Sera from the DNA EP group and from the SI group were
able to recognize in immunoblotting the p36 DHBV L protein from
concentrated DHBV particles in a similar manner as the speciﬁc
anti-DHBV L monoclonal antibody used as a positive control (Fig. 5).
Interestingly, the antibodies induced in the group immunized by
pDNA EP showed a better recognition of the major form (p36) of
the DHBV L protein (Fig. 5) as compared with antibodies induced by
SI. In addition, only antibodies elicited by EP were able to recognize
the minor form (p28) of the DHBV L protein. These data suggest
that antibodies generated by in vivo DNA EP could have a higher avid-
ity for the DHBV L envelope protein form than antibodies generated
following SI.Fig. 4. DNA dose effect on kinetics of humoral response elicited either by in vivo EP or
conventional injection. The mean anti-preS responses for each duck group immunized
with pCI-preS/S at doses of 10, 50 or 150 μg either delivered by EP or SI are represented
by plain (___) and dotted (−−−−) lines, respectively. Antibody levels are expressed
as the log10 of mean end point titers obtained in ELISA test with the SD indicated for
each group at each time point. Black arrows indicate DNA injections.Enhancement of neutralizing humoral response by in vivo DNA EP
Next, we asked whether the delivery of high or low pDNA doses by
EP could modulate the neutralizing efﬁcacy of anti-preS responses to
DHBV in PDH cultures. Therefore, we compared the neutralizing efﬁ-
cacy of sera from duck groups immunized with two different doses
(150 or 10 μg) of pCI-preS/S plasmid administrated either by EP or
by SI.
As shown in Fig. 6, all dilutions (1/4, 1/8, 1/16, 1/32, 1/64) of sera
from ducks immunized with high dose DNA (150 μg) by EP were able
to completely neutralize DHBV infectivity. Based on the total area
under the curve of DHBV levels in cell supernatants, a decrease of
100% of released virus was observed in PDH infected with virus prein-
cubated with any dilution of sera (1/4 to 1/64) from the high dose EP
group as compared with mock-preincubated inoculum. In contrast, in
sera from ducks immunized by SI with the same DNA dose, 100% of
neutralizing efﬁcacy was obtained only when the sera were diluted
to a minimal dilution of 1/4. The neutralizing capacity of these sera
decreased gradually when further diluted to reach 77% of efﬁcacy at
maximal dilution (1/64) whereas sera from the EP group were signif-
icantly (p=0.003) more effective and remained 100% neutralizing.Fig. 6. In vitro neutralizing activity of sera from DNA-immunized ducks. Primary duck
hepatocyte cultures (PDHs) were infected with DHBV-positive inoculum that was pre-
incubated either with culture medium (mock) or different dilutions of pooled sera
from ducks immunized with 150 or 10 μg of plasmid DNA by in vivo EP or SI, brought
to anti-preS titers of 5120 and 640, respectively. Five dilutions of each pool of sera
(1/4, 1/8, 1/16, 1/32, 1/64) collected at week 9 were prepared and incubated with
DHBV inoculum prior to PDH inoculation. The release of viral particles was quantiﬁed
in PDH supernatant by dot-blot hybridization. The area under the curve of released
DHBV DNA levels in supernatants at days 3–6, which reﬂects total viral secretion,
was used to calculate the percentage of neutralization.
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to neutralize the DHBV infectivity up to 88%, whereas sera from the SI
group were not at all neutralizing (Fig. 6). Thus, higher anti-preS ti-
ters generated in ducks immunized with 10 μg of pDNA by EP corre-
lated with a higher neutralizing capacity, whereas lower anti-preS
titers generated in the SI group were not neutralizing (Figs. 4 and
5). These results indicate a good correlation between the two re-
sponses. Taken together, these results suggest that delivery of pDNA
by EP dramatically improved the neutralizing humoral response in-
duced with a low DNA dose.
Enhancement of the preS antigenic repertoire recognized by antibodies
generated by EP-based DNA delivery
To better understand the differences in neutralizing efﬁcacy be-
tween antibodies induced by different DNA doses (150, 10 μg) admin-
istrated either by EP or SI, we compared, by peptide scanning
(pepscan) analysis, the antigenic regions (ARs) of preS protein recog-
nized by these antibodies. Duck sera from all immunized groups,
taken at week 12 (Fig. 4), were screened for their reactivity with
overlapping 9-mer peptides spanning the entire DHB preS region
(peptides 1 to 77) (Table 1). The scans in Fig. 7 illustrate the reactivity
obtained with sera from duck groups immunized with 150 μg or 10 μg
of pDNA either by EP or SI (panels A, B C and D respectively). The
scans obtained with sera of ducks within each group showed some
differences in the individual variation in peptide recognition and in
the intensity of peptide reactivity. Despite some differences in the in-
dividual bird to bird responses, sera from ducks immunized withTable 1
Amino acid sequences of the overlapping DHB preS synthetic peptides used for Pepscan
analysis.
Peptide location aa Peptide sequence Peptide location Peptide sequence
1–9 MGQHPAKSM 79–87 TPQEIPQPQ
3–11 QHPAKSMDV 81–89 QEIPQPQWT
5–13 PAKSMDVRR 83–91 IPQPQWTPE
7–15 KSMDVRRIE 85–93 QPQWTPEED
9–17 MDVRRIEGG 87–95 QWTPEEDQK
11–19 VRRIEGGEI 89–97 TPEEDQKAR
13–21 RIEGGEILL 91–99 EEDQKAREA
15–23 EGGEILLNQ 93–101 DQKAREAFR
17–25 GEILLNQLA 95–103 KAREAFRRY
19–27 ILLNQLAGR 97–105 REAFRRYQE
21–29 LNQLAGRMI 99–107 AFRRYQEER
23–31 QLAGRMIPK 101–109 RRYQEERPP
25–33 AGRMIPKGT 103–111 YQEERPPET
27–35 RMIPKGTLT 105–113 EERPPETTT
29–37 IPKGTLTWS 107–115 RPPETTTIP
31–39 KGTLTWSGK 109–117 PETTTIPPS
33–41 TLTWSGKFP 111–119 TTTIPPSSP
35–43 TWSGKFPTL 113–121 TIPPSSPPQ
37–45 SGKFPTLDH 115–123 PPSSPPQWK
39–47 KFPTLDHVL 117–125 SSPPQWKLQ
41–49 PTLDHVLDH 119–127 PPQWKLQPG
43–51 LDHVLDHVQ 121–129 QWKLQPGDD
45–53 HVLDHVQTM 123–131 KLQPGDDPL
47–55 LDHVQTMEE 125–133 QPGDDPLLG
49–57 HVQTMEEIN 127–135 GDDPLLGNQ
51–59 QTMEEINTL 129–137 DPLLGNQSL
53–61 MEEINTLQN 131–139 LLGNQSLLE
55–63 EINTLQNQG 133–141 GNQSLLETH
57–65 NTLQNQGAW 135–143 QSLLETHPL
59–67 LQNQGAWPA 137–145 LLETHPLYQ
61–69 NQGAWPAGA 139–147 ETHPLYQSE
63–71 GAWPAGAGR 141–149 HPLYQSEPA
65–73 WPAGAGRRV 143–151 LYQSEPAVP
67–75 AGAGRRVGL 145–153 QSEPAVPVI
69–77 AGRRVGLSN 147–155 EPAVPVIKT
71–79 RRVGLSNPT 149–157 AVPVIKTPP
73–81 VGLSNPTPQ 151–159 PVIKTPPLK
75–83 LSNPTPQEI 152–161 IKTPPLKKK
77–85 NPTPQEIPQ150 μg of pCI-preS/S by EP recognized 10 major antigenic regions :
AR1 (aa 9–31), AR2 (aa 25–43), AR3 (aa 37–51), AR4 (aa 53–65),
AR5 (aa 61–79), AR6 (aa 81–95), AR7 (aa 89–107), AR8
(aa 113–129), AR9 (aa 131–149) and AR10 (aa 145–159), as shown
in Fig. 7A. Moreover, antibodies induced by EP were highly reactive
to AR7. The reactivity spectrum of sera from ducks immunized with
the same DNA dose (150 μg) delivered by SI differed slightly
(Fig. 7B). In fact, these sera recognized all the ARs except AR4 and
AR10, although the recognition of some ARs was less broad and less
intense as compared to sera from EP group (Fig. 7B). Overall, immuni-
zation with high (150 μg) pDNA dose, delivered either by EP or SI, eli-
cited antibodies that recognize a broad range of B-cell epitopes on the
preS protein. Interestingly, antibodies induced in the two groups im-
munized with 150 μg of pCI-preS/S were highly reactive to AR5, AR6,
AR7 and AR8 (Figs. 7A and B). These regions correspond to neutraliza-
tion epitopes on the preS protein that have been previously identiﬁed
by us and others. The AR5 almost coincide with a neutralization epi-
tope 58T-W65 described by Yuasa et al. (Yuasa et al., 1991). Similarly,
AR6, AR7 and AR8 coincide respectively with the neutralization epi-
topes 83I-P90, 100F-R107 and 112T-P120 previously identiﬁed by us
using mouse monoclonal antibody or polyclonal rabbit antibody
that induces 100% protection in vivo (Chassot et al., 1993).
Concerning immunization with a low DNA dose (10 μg), delivery
by EP induced antibodies that recognized all ARs (AR1, AR2, AR4 to
AR10) except AR3, including high reactivity to neutralization epitopes
AR5, AR7 and AR8 (Fig. 7C). Sera from this group (10 μg DNA/EP)
showed less reactivity for some ARs compared to sera from the
150 μg DNA/EP group, as illustrated for AR4 and AR6 (Fig. 7C). How-
ever, the reactivity spectrum of antibodies induced by the same
DNA dose (10 μg), administrated this time by SI, appeared extremely
narrow and was restricted to only one of these ARs (AR7). In addition,
recognition of the neutralizing epitope AR7 was restricted to 2 out of
4 ducks immunized with 10 μg of DNA by SI. These results clariﬁed
why pooled sera from group 10 μg DNA/SI were completely unable
to neutralize the DHBV infectivity in vitro as compared with sera
from group 10 μg DNA/EP or other groups (Fig. 7). Overall, even a
very low DNA dose delivered with EP was able to maintain biological
properties of generated antibodies. These antibodies recognized a
broad range of neutralization epitopes as well as those elicited with
a high DNA dose. In contrast, delivery of 10 μg of low dose DNA by
the SI method did not generate broadly reactive antibodies.
Discussion
In this study we demonstrated, using the DHBV model, that ad-
ministration of pDNA by in vivo electroporation dramatically en-
hanced the magnitude, breadth and neutralizing potency of humoral
responses against hepadnaviral large envelope protein. EP-based
pDNA delivery induced a more rapid onset and higher magnitude of
anti-preS antibody response. In addition, pDNA delivery with EP re-
quired fewer immunizations (2 DNA administrations) to reach signif-
icantly higher anti-preS antibody titers that were 16-fold greater than
SI of the same pDNA dose. A similarly high-level antibody response to
HBV envelope protein (HBsAg) following delivery by EP was observed
in several animal models such as mice, rabbit, sheep and rhesus-
macaques (Babiuk et al., 2007; Luxembourg et al., 2006; Zhao et al.,
2006). Regarding the dose effect of pDNA administrated by EP, the
anti-preS responses were dose dependent. In addition, EP improved
considerably the dose efﬁciency of the pDNA vaccine, since this deliv-
ery method was able to induce an antibody response comparable in
magnitude to SI even with a 15-fold lower dose of pDNA (150 versus
10 μg). Moreover, in comparison with SI, a stronger anti-preS anti-
body response was observed with a 3-fold lower dose of pDNA
(150–50 μg) when delivered with EP. These ﬁndings are consistent
with those of other studies where EP was shown to induce superior
and long-lasting immunogenicity compared to SI even at relatively
Fig. 7. Screening of duck antibodies for their reactivity to overlapping 9-mer peptides spanning the entire sequence of DHB preS envelope protein by pepscan analysis. Antisera from
ducks immunized with A) 150 μg of pCI-preS/S by EP, B) 150 μg of pCI-preS/S by SI C) 10 μg of pCI-preS/S by EP or D) 10 μg of pCI-preS/S by SI, were taken at week 12 (Fig. 4) and
were screened for their reactivity with overlapping 9-mer peptides covering the entire DHB preS region (1 to 161 aa). The anti-preS titer of each animal at week 12 is shown in
brackets. Cumulative optical density values as determined by the pepscan analysis are shown. Background signal of control and nonreactive peptides has been subtracted before
graphic representation. AR1 to AR10 indicate the positions of recognized antigenic regions (AR).
66 G. Khawaja et al. / Virology 425 (2012) 61–69low DNA doses (Luckay et al., 2007; Luxembourg et al., 2008b; Rosati
et al., 2008). We have not investigated the impact of this delivery
method on duck cellular immune responses since tools for such stud-
ies are under development.
The mechanisms by which EP enhanced the breadth and magni-
tude of humoral response are likely multiple. We showed in this
study that EP delivery of pDNA increases and prolongs antigen ex-
pression, induces local inﬂammation and inﬁltration of CD3+ T
cells, and causes limited local tissue damage. Clearly, the increased
and prolonged protein expression levels at the injection site are re-
sponsible for increasing the overall amount of antigen available for
priming of immune responses. Given the absence of damage with
EP or DNA alone, it is the combination of these two that leads to
local tissue damage and the inﬁltration of APCs, as well as the recruit-
ment of muscle-inﬁltrating CD3+ cells, which play an important rolein increasing the efﬁcacy of pDNA EP. Indeed, these data suggest that
the highly localized tissue damage and antigen expression results in a
potent inﬂammatory response that most likely assists in the priming
and recruitment of CD3+ T cells. These observations are consistent
with those of other reports where an inﬂammatory response at the
antigen production site has been suggested to create an environment
that is favorable to the establishment and/or maintenance of the im-
mune response to the DNA vaccine (Babiuk et al., 2004; Widera et al.,
2000).
A recent study in the woodchuck model has shown the ability of
EP-based delivery to enhance both arms of immune responses to
DNA vaccines for WHV, a hepadnavirus closely related to HBV. This
study reported the induction of high antibody titers and strong T-
cell responses with a shift toward a Th1 response following pDNA
EP which could be very useful for the development of a therapeutic
67G. Khawaja et al. / Virology 425 (2012) 61–69HBV vaccine (Liu et al., 2011). However, the neutralizing efﬁcacy of
the humoral response to the WHV DNA vaccine was not investigated
(Liu et al., 2011). Our study provided the opportunity to evaluate for
the ﬁrst time the DNA dose effect of EP-based delivery on the neutral-
izing antibody response against hepadnaviral proteins using PDH that
are highly susceptible to DHBV infection. Importantly, EP dramatically
enhanced neutralizing potency of humoral response since antibodies
elicited with low pDNA dose (10 μg) were highly neutralizing, where-
as SI of the identical pDNA dose was not able to generate neutralizing
antibodies. Firstly, our results provide evidence that EP increases neu-
tralizing antibody responses against hepadnaviral proteins. These
ﬁndings are consistent with previous observations demonstrating
that EP-based pDNA delivery facilitates the induction of neutralizing
antibodies against different pathogens (Chen et al., 2008; Dupuy et
al., 2011; Gardiner et al., 2009; Livingston et al., 2010; Luxembourg
et al., 2008a; Mallilankaraman et al., 2011) and now extend them to
hepadnavirus. Secondly, our data illustrate that more effective deliv-
ery of a low pDNA dose by EP induces a potent neutralizing response
and further reinforces the ﬁnding that EP improves the dose efﬁcien-
cy of a DHBV DNA vaccine.
Another important aspect of this study concerned the identiﬁca-
tion, at the amino acid level, of major antigenic preS regions recog-
nized by antibodies elicited either by pDNA EP or SI. The difference
between these two immunization methods regarding the induction
of neutralizing antibodies was clariﬁed using pepscan analysis. We
have previously used this approach for the determination of ARs of
DHBV core protein and preS protein recognized by antibodies elicited
in DHBV-carriers and during resolution of viral infection, respectively
(Chassot et al., 1994; Thermet et al., 2004). In the present study, we
demonstrate that antibodies generated by EP delivery of high dose
pDNA were able to recognize 10 major preS ARs whereas the reactiv-
ity spectrum of antibodies induced by SI of the same dose was less
broad and to a lesser extent. Interestingly, some of the common re-
gions (AR5, AR6, AR7 and AR8) recognized by sera from groups im-
munized either by EP or SI coincide respectively with preS
neutralizing epitopes (58T-W66, 83I-P90, 100F-R107 and 112T-P120)
that have been previously identiﬁed by us and others (Chassot et al.,
1993; Yuasa et al., 1991). These ﬁndings are helpful to explain the
ability of antibodies generated by EP or SI delivery of high dose
pDNA to neutralize DHBV infectivity in PDH cultures. The higher neu-
tralizing response induced by EP of high and low pDNA dose may be
explained by the broader and better recognition of preS B-cell epi-
topes when compared to SI. Such antibody response induced by EP
mimics that observed in ducks during the resolution of DHBV infec-
tion (Chassot et al., 1994). In addition, the better recognition of in-
duced antibodies by EP to the minor and major forms of DHBV L
preS/S envelope protein can be also explained by the recognition of
a broader range of preS B-cell epitopes as compared to SI.
Interestingly, concerning the delivery of low dose (10 μg) of
pDNA, EP was able to maintain the recognition of a broad range of
B-cell epitopes, including neutralizing epitopes, comparable with
that observed with the high DNA dose. However, immunization
with such low pDNA dose by SI induced anti-preS antibodies with
an epitope pattern restricted to only one AR (AR7) that was recog-
nized by only 2 out of 4 animals of the group, which support their
poor neutralizing ability in vitro. The difference between the reactiv-
ity spectrum of antibodies induced by EP or SI was not related to
their anti-preS titers, since as shown in Fig. 7, these titers at week
12 differed only slightly between animals immunized with the same
pDNA dose. Overall, these results provide a ﬁrst evidence that EP is
able to induce, even with low pDNA dose, an antibody response that
recognize a broader repertoire of B-cell epitopes, including neutraliz-
ing epitopes, as compared to SI. Such an increase in potency of DNA
vaccine, in a dose efﬁcient manner, provides encouragement that EP
may preserve the expression of plasmid-encoded antigen and im-
mune responses to DNA vaccines across species including humansat clinically feasible DNA dose. In previous reports, induction of a
broader repertoire of responses by pDNA EP has been demonstrated
only for T-cell epitopes (Kim et al., 2008; Luckay et al., 2007;
Luxembourg et al., 2006) and now our results allow to extend these
ﬁndings to B-cell epitopes. These ﬁndings are relevant to therapeutic
vaccination against chronic HBV infection, since multi-speciﬁc CTL re-
sponses are essential for intrahepatic viral clearance and highly neu-
tralizing antibodies are particularly important for clearance of
circulating viral particles and prevention of reinfection (Chisari et
al., 2010). Based on these results, an evaluation of the therapeutic
beneﬁts of EP-based pDNA in the chronic DHBV infection duck
model is warranted.
Materials and methods
Animals
DHBV-free Pekin ducklings (Anas domesticus) were purchased
from a commercial supplier. Duck experiments were performed in ac-
cordance with the guidelines for animal care at the National Veteri-
nary School of Lyon (Marcy l'Etoile, France).
DNA vaccine
The previously described pCI-preS/S plasmid, encoding the DHBV
preS/S large envelope protein (Rollier et al., 1999) was used for ge-
netic immunization of ducks. The empty plasmid pCI representing
the plasmid backbone with no inserted gene was used as a negative
control. Both pCI-preS/S and pCI plasmids were grown in E. coli, puri-
ﬁed by an Endotoxin Free Giga Prep Kit (Qiagen, Hilden, Germany),
resuspended in ﬁltered water and quantiﬁed by spectrophotometry.
Duck DNA electroporation and immunization procedures
In the ﬁrst study, ﬁve week-old naïve Pekin ducks were randomly
divided into two vaccinated groups (5 ducks/group) and a control
group (2 ducks/group). Ducks were anesthetized with a mixture of
Dormitor/Zoletil and shaved over the two sides of the breast-bone
to prepare the site of vaccination. Treated groups received intramus-
cularly a total of 300 μg pCI-preS/S plasmid in 600 μl of PBS per injec-
tion, delivered either by a TriGrid electroporation (EP) device (Ichor
Medical Systems, San Diego, CA) (group 1) or by standard injection
(SI) (group 2) (Fig. 1A). The control group received an i.m. injection
of the same dose i.e. 300 μg of empty plasmid pCI by EP. For group
1, DNA injections were performed in two sites; in breast and shoul-
der. EP was applied with a four-needle electrode array (designed spe-
ciﬁcally for the duck model) using the TriGrid delivery device, with
6 mm intraelectrode spacing and electrical stimulation as previously
described (Luxembourg et al., 2008b). For group 2, DNA immuniza-
tion consisted of multiple injections (6 sites) in breast and shoulder
as described previously (Rollier et al., 1999). Identical booster doses
were administered at the same site 4 and 8 weeks later, followed by
a delayed boost after 30 weeks (Fig. 1C).
To investigate the DNA dose effect, a second study was performed
in which DHBV-free Pekin ducks divided randomly into six groups (4
ducks/group) received i.m. injections of different doses; 150, 50 or
10 μg of pCI-PreS/S were delivered either by EP or SI (Fig. 1B). Immu-
nizations were conducted three times at weeks 0, 4, 8 (Fig. 1C).
Immunohistological examination of breast muscle at injection sites
Three ducks received pCI-preS/S plasmid (300 μg pDNA/600 μl
PBS) or PBS alone (no DNA/600 μl PBS) either by SI or in vivo EP as de-
scribed above. Six days post immunization, animals were euthanized
with an overdose of Zoletil and muscle samples were obtained from
all injections sites on these animals. Breast and shoulder muscles
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velop protein expression by immunohistochemistry. Tissues were
ﬁxed in 10% neutral buffer formalin, dehydrated, and embedded in
parafﬁn. 5 mm sections were cut, mounted onto glass slides and
stained with hematoxylin and eosin (H&E), an antibody to human
CD3 (Clone F7.2.38, DakoCytomation) or with a previously described
rabbit polyclonal antiserum raised against DHB preS polypeptide
(Lambert et al., 1991).
Detection of speciﬁc anti-preS antibodies by ELISA
The humoral anti-preS response of ducks was detected by a direct
ELISA using microtiter plates (Falcon, Probind) coated with the re-
combinant DHBV preS polypeptide as described previously (Rollier
et al., 2000). The antibody titers were determined on the serum sam-
ples of each duck at each time of the follow-up using an end-point di-
lution ELISA titration assay described previously (Rollier et al., 2000).
Immunoblotting analysis of generated antibodies
DHBV particles or mock (negative control) were concentrated by
sucrose cushion (10%) ultracentrifugation of LMH-D2 or LMH super-
natants (mock), respectively. The equivalent of 5 μg of denaturized
proteins were separated on a 12% SDS polyacrylamide gel and subse-
quently electrotransferred to nitrocellulose ﬁlters. Immunoblotting
was performed using pooled sera from each immunized duck group,
which were brought back to the same anti-preS titer and diluted to
1:30. After washes, ﬁlters were incubated with anti-duck immuno-
globulin G peroxidase conjugates (1:3000), and visualized by an ECL
chemo-luminescence detection kit (Amersham, Courtaboeuf, France).
In vitro neutralizing activity of sera from ducks immunized by EP or SI
The neutralizing activity of duck sera was tested in duplicate in
primary duck hepatocyte (PDH) cultures, which were infected with
DHBV-positive serum (2×109 viral genome equivalents/well) that
had been preincubated overnight at room temperature with various
dilutions (1/4, 1/8, 1/16, 1/32, 1/64) of pooled sera from each immu-
nized duck group of the dose effect study, collected one week after
the last immunization (week 9) or with cell culture medium (nega-
tive control) as described previously (Lambert et al., 1991). The re-
lease of virions was followed during 6 days by quantitative dot-blot
hybridization of DHBV DNA. The area under the curve of released
DHBV DNA levels in PDH supernatants at days 3–6 reﬂects total
viral secretion and was used to calculate the percentage of neutraliza-
tion as previously described (Lambert et al., 1991). Neutralization
was considered effective when the reduction of total released virions
was at least 50%.
Peptide scanning analysis of induced antibodies
Preparation of biotinylated peptides
The antibody responses of individual duck sera to DHBV preS lin-
ear epitopes were analyzed using the Pepscan method (Skinner et
al., 1999). A pepset of 77 overlapping nonapeptides (9 residues),
spanning the entire DHBV preS protein (residues 1 to 166), were syn-
thesized by Mimotopes peptide company (UK) in the format Biotin-
SGSG-PEPTIDE-amide. These 9-mers peptides were designed with
an overlap of 7 amino acids of the preS protein sequence as shown
in Table 1 to ensure that all potential epitopes would be identiﬁed.
A nonoverlapping peptide was used as an unrelated control peptide.
Initially, each biotinylated peptide was solubilized in 400 μl of di-
methyl sulfoxide/water (80%/20%) and 10 μl was used for each assay
to make a 1:12 stock peptide solution diluted in 0.01 M sodium
phosphate-buffered saline (PBS) pH 7.2 containing 0.1% sodium
azide and 0.1% Tween 20. The biotinylated peptides were tested forantibody binding by ELISA according to the manufacturer's instruc-
tions, as described subsequently.
Pepscan assay
Brieﬂy, streptavidin (Sigma) was diluted to 10 μg/ml in 0.1 M so-
dium bicarbonate buffer pH 9.6 and dispensed at 100 μl/well into
96-well microtiter plates (Nunc-Immuno® MaxiSorb), which were
incubated overnight at room temperature (RT). Plates were then
rinsed three times in wash buffer consisting of PBS with 0.1% Tween
20. The plates were blocked with 200 μl/well of PBS containing 1% bo-
vine serum albumin (BSA) for 2 h at 37 °C and the rinse was repeated.
100 μl of each of the diluted biotinylated peptide solutions (1:12)
were transferred into the corresponding well positions of the plate
and incubated 1 h at RT with shaking. After the plates were rinsed,
100 μl/well of serum from immunized ducks, diluted each to 1:40 in
wash buffer containing 0.1% sodium azide was incubated for 2 h.
Plates were rinsed and 100 μl/well of secondary antibody, (peroxi-
dase-labeled afﬁnity-puriﬁed goat anti-duck IgG (KPL, 0.1 mg/ml
stock solution) diluted to 1:500 in wash buffer containing 1% sheep
serum and 0.1% BSA was incubated for 1 h. After being rinsed, the
plates were loaded for 45 min with 100 μl/well of 2,2′-azino-bis-[3-
ethylbenzthiazolinsulfonate] (ABTS, Pierce) in substrate buffer
according to the manufacturer's protocol. The plates were read at
405 nm and data were processed by subtraction of mean values plus
two standard deviations obtained with background reactivity of
duck serum with the unrelated control peptide. The signals were
expressed as optical density units (O.D.) (Skinner et al., 1999).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 4.0
(San Diego, CA). The mean anti-preS titers of experimental groups
were compared at each sampling using a nonparametric, two-tailed,
Mann–Whitney U test. In addition, the Student t test was used to as-
sess signiﬁcance in the neutralization assay. P values≤0.05 were con-
sidered statistically signiﬁcant.
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